Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs Target Corporation (TGT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs Target Corporation — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B), while Target Corporation trades at $155.45 (market cap $69.05B). The key difference: Target Corporation is far larger — about 9.2× Spyre Therapeutics Inc. Common Stock's market cap, and Target Corporation pays a 3.05% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and Target Corporation for 137 Days on average.
| SYRE | TGT | |
|---|---|---|
Market Cap | $7.52B | $69.05B |
Volume | 1,441,031 | 3,728,482 |
Sector | Health | Consumer Staples |
52-Week High | $108.92 | $169.90 |
52-Week Low | $22.18 | $83.68 |
Typical Hold Time | 0 Days | 137 Days |
Enterprise Value | $6.52B | $82.33B |
Dividend Yield | — | 3.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Target (TGT) trades at $155.30, up 1.13% today, with a neutral technical signal and key resistance at $155. The stock shows strong profitability with a 26.41% ROE and 4.08% net margin, supported by three consecutive quarterly earnings beats. Recent news highlights holiday price cuts to capture market share, while analyst consensus is evenly split between Buy and Hold ratings.
The outlook is balanced: valuation appears reasonable with a P/E of 15.77, and dividend stability offers income appeal, but competitive pressures and margin compression from aggressive pricing pose risks. Upside to the $166.95 consensus target depends on successful execution of growth initiatives amid a challenging retail environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About Target Corporation
With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →
